IP Verse

Novartis Pharma Ag patent opposition analysis

Latest patents of Novartis Pharma Ag opposed by its competitors

The following table provides an overview of the latest patents of Novartis Pharma Ag that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP2784084Oct 4, 2023Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof5
EP3345602Apr 6, 2022Rapamycin Derivative For Treating Advanced Solid Tumours3
EP3003316Jul 22, 2020Combination Therapies For Cancer1
EP2340828Jul 15, 2020Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor8
EP3351246Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis9
EP3342411Aug 21, 2019Rapamycin Derivative For Treating Pancreas Cancer10
EP3143995Dec 5, 2018A Rapamycin Derivative For Treating Lung Cancer7
EP1983984Mar 7, 2018Tuberous Sclerosis Treatment4

Top competitors of Novartis Pharma Ag